REGENERX BIOPHARMACEUTICALS
RGN
RGN was delisted on the 22nd of December, 2010.
3 hedge funds and large institutions have $33K invested in REGENERX BIOPHARMACEUTICALS in 2018 Q3 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
50% more funds holding
Funds holding: 2 → 3 (+1)
3% less capital invested
Capital invested by funds: $34K → $33K (-$1K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CG
Colony Group
Boston,
Massachusetts
|
+$2K |
Top Sellers
RGN Hedge Fund Activity: Q3 2018 in Review
3 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in REGENERX BIOPHARMACEUTICALS (RGN) for Q3 2018, worth a combined $33K — down 2.9% from $34K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new RGN positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Colony Group, opening a new position worth an estimated $2K.
- 3 institutional investors held REGENERX BIOPHARMACEUTICALS (RGN) as of Q3 2018, up from 2 in Q2 2018.
- Funds reported $33K of REGENERX BIOPHARMACEUTICALS stock for Q3 2018, down 2.9% quarter-over-quarter.
- 1 fund opened new REGENERX BIOPHARMACEUTICALS positions in Q3 2018 and 0 closed out, a net change of +1 holder.
- The largest REGENERX BIOPHARMACEUTICALS buyer in Q3 2018 was Colony Group, an estimated $2K added.
Based on aggregated 13F filings for Q3 2018.